Six Premier Craft Beverage Equipment Suppliers Merge in $100 Million Deal to Launch First-Ever One-Stop-Shop for All Craft Beverage Needs
20.4.2023 14:30:00 EEST | Business Wire | Press release
Lotus Beverage Alliance, a collective of experienced craft beverage equipment manufacturing companies, today announced that it has officially launched as a company. Six leading American craft beverage equipment suppliers have merged in a $100 million deal to create Lotus Beverage Alliance. The combined capabilities of Lotus Beverage Alliance will enable beverage manufacturers of all sizes to access the most comprehensive array of products spanning every step of production for craft beer, wine, hard cider, spirits, cold brew coffee, ready-to-drink cocktails, kombucha, CBD/THC-infused drinks, and sake beverages.
The six merged companies, Alpha Brewing Operations, GW Kent, Twin Monkeys, Stout Tanks and Kettles, Brewmation, and Automated Extractions, are leaders in craft beverage equipment manufacturing and offer essential infrastructure and technology for diversifying the craft beverage industry. The five founders of the six companies will remain in senior leadership positions at Lotus: Matt Rennerfeldt, John Watt, Kevin Weaver, Josh Van Riper, and Randy Reichwage. John Ansbro, an industry veteran with more than 30 years of experience in equipment manufacturing, has been named Chief Executive Officer for Lotus. Ansbro has held senior executive positions at Alfa Laval, Johnson Controls, and the GEA Group.
“Lotus has everything craft beverage creators need to produce the amazing artisanal products they love, for people who love them,” said John Ansbro, CEO of Lotus Beverage Alliance. “Our team’s proven industry experience includes a deep bench of experts helping to optimize the production of handcrafted beverages for consumers to enjoy.”
Lotus Beverage Alliance brings these leading equipment makers under one roof to become the only end-to-end provider dedicated to crafting possibilities for beverage makers, from nationally-distributed beverage purveyors to the everyday craft enthusiast. Lotus Beverage Alliance produces 1,500+ top-shelf products, including turn-key brewhouse production equipment, 304 stainless steel conical fermenters, brew kettles, IBC totes, multi-capacity tanks, mash tuns, brite tanks, canning systems, automation and control systems, packaging, thermal processes and sanitation equipment, raw ingredient supply, parts, and more.
In another industry first, Lotus introduced a proprietary financing program that offers customers affordable financing options, removing cost barriers for startups and smaller beverage producers. Credit approvals typically take less than 24 hours to provide clients with maximum flexibility.
“What a bold vision to pull together such well-respected leaders of each of their respective craft beverage supplier channel segments. The result of this merger for craft beverage makers is sure to be exponential growth and continued beverage innovation,” said Banjo Bandolas, Director of Advertising and Sales at ProBrewer.com. “Lotus appears to be a first-mover by creating a one-stop-shop for craft brewers and companies moving into ‘beyond beer’ products. I look forward to seeing where it evolves.”
Beverage makers who select Lotus Beverage Alliance as their trusted equipment partner can expect:
- Responsive and expert customer service
- A one-stop-shop supply chain for all production needs
- Ready-to-ship production parts and equipment
- High-performance equipment with extended life cycles
- Seamless equipment integration with several third-party brands
- Opportunities for reduced operating costs and downtime through automation
- Greater uptimes and efficiencies in production processes
- Post-purchase technical and operations support
- Proprietary purchase financing program with typical approval in 24 hours
Lotus Beverage Alliance offers extensive support for startups and scale-ups, including:
- Brewing and Distilling
- Quick Ship Equipment and Parts
- Packaging
- Automation and Controls
- Extraction Processing
- Beverage Production Support
Following the six-way merger, the Lotus Beverage Alliance ownership structure includes the founders from all six businesses. Additionally, Lotus has implemented an employee ownership program, at no cost to the employees. Employee ownership has been extended to every single employee throughout the organization. Research has shown that broad-based employee ownership programs improve worker retention, reduce income disparity, and result in higher margins, as well as improved growth and operating efficiencies across various aspects of a business. Lotus collaborated with Ownership Works (https://ownershipworks.org/) in this employee ownership program’s creation. The Lotus merger was facilitated by Ronin Equity Partners, a New York-based investment firm with a long-term growth focus. Ronin is also an investor in Lotus.
Lotus Beverage Alliance will be an exhibitor at the Specialty Coffee Expo in Portland, Oregon, Apr. 21–23, at Booth #456; and at the Craft Brewers Conference in Nashville, Tennessee, May 7-10, 2023 at Booths #500 and #945.
About L otus Beverage Alliance:
Lotus Beverage Alliance is a collective group of experienced companies with extensive knowledge and professional insight into the craft beverage industry. The organization was formed to bring excitement and resources to craft brewing companies by providing an advanced and comprehensive product line, knowledgeable technical guidance, immediate equipment and parts availability, and an excellent customer service team. To learn more about Lotus Beverage Alliance, please visit lotusbevalliance.com. Crafting possibilities.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230420005259/en/
Contact information
For Media Inquiries, Please Contact:
Craft beer media:
Jesse P. Cutler, JP Cutler Media, 415.318.9663, jesse@jpcutlermedia.com
Wine/spirits/specialty beverage media:
Michelle Barry, Chameleon Collective
603.809.2748
LotusBeverage@chameleon.co
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
